Biogen Inc
USUSDBiogen Inc (US:BIIB) — Biotechnology: Biological Products (No Diagnostic Substances). Количество бирж, на которых торгуются акции компании: 3. На этой странице — цена и график, дивиденды, крупнейшие держатели и история количества акций.
О компании
- Сайт
- biogen.com
- Взаимодействие с инвесторами
- investors.biogen.com/
- Сектор
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Штаб-квартира
- Cambridge, United States
- Генеральный директор
- Michel Vounatsos
- Сотрудники
- 7 500
- Основана
- 1978
- Акций в обращении
- 147.75 млн на 2026-07-27
- Свободное обращение
- 147.22 млн
- Рыночная капитализация
- 33.79 млрд USD
- Инсайдеры
- 0.19%
- Институциональные инвесторы
- 99.5%
- Отрасль (SIC)
- Biological Products, (No Diagnostic Substances)
- Правовая форма
- XTIQ
- ISIN
- US09062X1037
- LEI
- W8J5WZB5IY3K0NDQT671
- Коэффициент выплат
- 0%
- FCF
- 2.42 млрд USD
- Долг
- 6.29 млрд USD2.6 г. FCF
- Стаж дивидендов
- —
- Прибыль, FCF и выплаченные дивиденды — за 12 месяцев до 31.03.2026 (последний отчёт компании).
Описание
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Дивиденды
Выплаты дивидендов не обнаружены (проверено 10.10.2026). Компания, вероятно, не выплачивает дивиденды.
Новости этой недели
Новостей с сайта компании пока нет.
Крупнейшие держатели
| Держатель | Доля | Акции | Дата отчета |
|---|---|---|---|
| FMR, LLC | 12.33% | 18.22 млн | 2026-06-30 |
| Blackrock Inc. | 10.82% | 15.99 млн | 2026-06-30 |
| Primecap Management Comp… | 10.26% | 15.15 млн | 2026-06-30 |
| Vanguard Capital Managem… | 6.53% | 9.65 млн | 2026-06-30 |
| VANGUARD CHESTER FUNDS-V… | 5.66% | 8.36 млн | 2026-06-30 |
| State Street Corporation | 4.97% | 7.34 млн | 2026-06-30 |
| Vanguard Portfolio Manag… | 4.47% | 6.6 млн | 2026-06-30 |
| Fidelity Contrafund | 3.37% | 4.98 млн | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 4.69 млн | 2026-06-30 |
| Geode Capital Management… | 3.01% | 4.45 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 3.83 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.17% | 3.2 млн | 2026-06-30 |
| Wellington Management Gr… | 2.11% | 3.12 млн | 2026-06-30 |
| VANGUARD HORIZON FUNDS-V… | 1.78% | 2.62 млн | 2026-06-30 |
| NORGES BANK | 1.75% | 2.58 млн | 2026-06-30 |
| VANGUARD SPECIALIZED FUN… | 1.71% | 2.53 млн | 2026-04-30 |
| Morgan Stanley | 1.63% | 2.41 млн | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 1.99 млн | 2026-07-31 |
| Fidelity Concord Street… | 1.29% | 1.91 млн | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.23% | 1.81 млн | 2026-08-31 |
| ALEXANDER SUSAN H (Offic… | ≈0.04% | 61 889 | 2026-02-06 |
| DORSA CAROLINE D (Direct… | ≈0.02% | 31 002 | 2025-06-17 |
| VIEHBACHER CHRISTOPHER (… | ≈0.02% | 29 924 | 2026-02-06 |
| ROWINSKY ERIC K. (Direct… | ≈0.02% | 25 844 | 2026-06-09 |
| MCDONNELL MICHAEL R (Chi… | ≈0.02% | 24 341 | 2025-02-10 |
| GREGORY GINGER (Officer) | ≈0.02% | 22 358 | 2026-02-06 |
| MURPHY NICOLE (Officer) | ≈0.01% | 19 611 | 2026-02-12 |
| SHERWIN STEPHEN A (Direc… | ≈0.01% | 15 193 | 2026-06-09 |
| KRAMER ROBIN C. (Chief F… | ≈0.01% | 11 471 | 2026-02-06 |
| MANTAS JESUS B (Director… | ≈0.01% | 11 263 | 2026-06-09 |
| Renaissance Technologies | — | — | — |
